Sign in
Taking peopleNo phase

Two kinds of shoulder replacement for shoulder osteoarthritis compared

Compares reverse and standard shoulder replacement in people with shoulder osteoarthritis.

Key facts

Who runs it
La Tour Hospital
Where
Switzerland1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Anatomic TSA vs RTSA for Glenohumeral Arthritis
Status
Recruiting
People taking part
296 people, planned
Started
1 Sept 2020
Expected to end
1 May 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Total shoulder arthroplasty
Record updated
22 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 65 to 85 with primary shoulder joint arthritis (glenohumeral osteoarthritis) and an intact rotator cuff. They will get either an anatomic or a reverse total shoulder replacement.

Age
65 to 85 years
Sex
All sexes
Disease stage
Primary glenohumeral arthritis with an intact rotator cuff and no important bone loss in the shoulder socket (glenoid).
Earlier treatment
People who had earlier shoulder surgery or revision surgery cannot join.

Main reasons for not taking part

  • B2 glenoid with > 80% posterior humeral head subluxation or more than 25 degrees neoglenoid retroversion, or B3 and C type glenoids
  • Full thickness rotator cuff tear, non-functioning deltoid muscle or axillary nerve damage
  • Acute or badly healed upper arm bone fracture, or a chronic locked dislocation
  • Rheumatoid arthritis, tumors, infection or neuropathic joints
  • Drug or alcohol abuse, or not able to follow the study procedures, for example due to dementia, language problems or not being able to have a CT scan

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • Primary glenohumeral arthritis,
  • Intact rotator cuff,
  • No important glenoid bone loss (cf exclusion criteria),
  • Patients between 65 and 85 years old
  • Informed Consent as documented by signature (Appendix Informed Consent Form)

Who cannot take part

  • Revision surgery or surgical antecedents,
  • Known or suspected non-compliance, drug or alcohol abuse,
  • Infection and neuropathic joints,
  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, contraindication for CT scan etc. of the participant,
  • B2 glenoid with > 80% posterior humeral head subluxation or greater 25 degrees neoglenoid retroversion,
  • B3 and C type glenoids,
  • Full thickness rotator cuff tear,
  • Acute or malunited proximal humeral fracture,
  • Chronic locked dislocation
  • Rheumatoid arthritis,
  • Tumors,
  • Axillary nerve damage,
  • Non-functioning deltoid muscle,
  • Glenoid vault deficiency precluding baseplate fixation,
  • Patients incapable of judgement or under tutelage,
  • Enrolment of the investigator, his/her family members, employees and other dependent persons

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 65 and 85 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

There are no published prospective studies that compared 2-year functional outcomes of RTSA and anatomic TSA for the treatment of primary glenohumeral osteoarthritis with intact rotator cuffs and no excessive glenoid retroversion. The primary goal of our prospective randomized study is to determine whether RTSA have at least as good results as anatomic TSA (non-inferiority), in patients with glenohumeral osteoarthritis, without rotator cuff tears nor significant glenoid retroversion.

The 2 groups in the trial

  • Anatomic TSAExisting treatment, for comparison

    The control group will receive through a deltopectoral approach an anatomic total shoulder arthroplasty (TSA) for a primary glenohumeral arthritis

    Treatment: Total shoulder arthroplasty

  • RTSATreatment being tested

    The experimental group will receive through a deltopectoral approach a reverse total shoulder arthroplasty RTSA for a primary glenohumeral arthritis

    Treatment: Total shoulder arthroplasty

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Anatomic Versus Reverse Shoulder Arthroplasty for Primary Glenohumeral Osteoarthritis. A Randomized Prospective Study
Plain-language title
Two kinds of shoulder replacement for shoulder osteoarthritis comparedGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT04629391, who can take part
Record updated
22 May 2026